#USA #Milford #Waters Corporation #Biosciences #Q3 2026

Waters Corporation Reports Third Quarter 2026 Financial Results

Waters Corporation, listed on the NYSE as WAT, has reported robust financial results for the third quarter of 2026, reflecting a total revenue of $1.767 billion. This revenue surpasses the guidance midpoint by $14 million, showcasing a strong organic revenue growth of 9% and an impressive 10% growth when measured in constant currency. Additionally, the company has shown that revenue from acquired businesses slightly exceeded expectations, contributing $896 million to the total.

The financial metrics reveal a diluted earnings per share (EPS) of $0.82, while the adjusted EPS showed a significant increase of 21% to $4.10, underlining the favorable performance compared to the prior year. The Analytical Sciences Division (ASD) posted an 8% growth as reported and 9% in constant currency, mainly driven by strong instrument and chemistry growth.

Division Performances

Analytical Sciences Division (ASD)

The ASD reported revenue of $703 million, an increase from $649 million in the third quarter of 2025. This growth can be attributed to effective product innovation and heightened customer demand in LC-MS instruments, which saw double-digit growth also driven by industry trends and expanded customer testing volumes.

Biosciences Division (WBD)

In the Biosciences Division, revenue reached $396 million, a slight increase from $387 million in the corresponding prior year period. This growth reflects a notable acceleration in year-over-year performance, particularly in research and clinical reagents, which both grew in high single digits.

Advanced Diagnostics Division (ADx)

The ADx, which includes the former BD Diagnostic Solutions business, reported solid growth as well, with revenue of $500 million, compared to $498 million the previous year. Additionally, the Clinical Business Unit within this division achieved $75 million in revenue, marking an increase from $64 million in Q3 2025.

Materials Sciences Division (MSD)

The MSD division also made significant strides, achieving revenue of $93 million, compared to $87 million in the same quarter the previous year, emphasizing the diverse growth across the organization.

Full-Year Guidance Updates

Looking ahead, Waters Corporation is optimistic about its financial trajectory. The company has revised its full-year 2026 guidance upwards, anticipating organic constant currency revenue growth in the range of 9.1% to 9.7%. The total reported revenue expectation is now between $6.479 billion and $6.497 billion. Notably, for the fourth quarter, the company forecasts organic constant currency revenue growth of around 7% to 9%.

Strategic Outlook for 2027

During the earnings conference call scheduled for today, Waters Corporation's management will outline a growth framework for 2027. This strategy involves leveraging emerging opportunities from reshoring initiatives, integrating synergies from recent acquisitions, and addressing demand driven by artificial intelligence. One significant recent acquisition announced is MOBILion Systems, Inc., which specializes in high-resolution ion mobility separation technology. This acquisition is poised to complement Waters' existing mass spectrometry portfolio, particularly expanding its capabilities in the proteomics sector.

Dr. Udit Batra, the company’s CEO, emphasized the commitment to achieving accelerated growth. He stated, "Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions. We are excited to ride on this growth momentum as we make advancements with new technologies."

Overall, the results from Waters Corporation in the third quarter of 2026 highlight not only a successful period of growth but also set the stage for an ambitious and strategically sound future. Investors can expect to see continued innovation and potential market improvement as the company navigates the coming quarters.